Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation

被引:169
作者
van Spriel, AB
Leusen, JHW
van Egmond, M
Dijkman, HBPM
Assmann, KJM
Mayadas, TN
van de Winkel, JGJ
机构
[1] Univ Utrecht, Med Ctr, Immunotherapy Lab, NL-3584 EA Utrecht, Netherlands
[2] Univ Utrecht, Med Ctr, Medarex Europe, NL-3584 EA Utrecht, Netherlands
[3] Univ Nijmegen Hosp, Dept Pathol, Nijmegen, Netherlands
[4] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA
关键词
D O I
10.1182/blood.V97.8.2478
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Receptors for human immunoglobulin (Ig)G and IgA initiate potent cytolysis of antibody (Ab)-coated targets by polymorphonuclear leukocytes (PMNs). Mac-1 (complement receptor type 3, CD11b/CD18) has previously been implicated in receptor cooperation with Fc receptors (FcRs). The role of Mac-1 in FcR-mediated lysis of tumor cells was characterized by studying normal human PMNs, Mac-1-deficient mouse PMNs, and mouse PMNs transgenic for human FcR. All PMNs efficiently phagocytosed Ab-coated particles, However, antibody-dependent cellular cytotoxicity (ADCC) was abrogated in Mac-1(-/-) PMNs and in human PMNs blocked with anti-Mac-1 monoclonal Ab (mAb). Mac-1(-/-) PMNs were unable to spread on Ab-opsonized target cells and other Ab-coated surfaces. Confocal laser scanning and electron microscopy revealed a striking difference in immunologic synapse formation between Mac1(-/-) and wild-type PMNs. Also, respiratory burst activity could be measured outside membrane-enclosed compartments by using Mac-1(-/-) PMNs bound to Ab-coated tumor cells, in contrast to wild-type PMNs. In summary, these data document an absolute requirement of Mac-1 for FcR-mediated PMN cytotoxicity toward tumor targets. Mac-1(-/-) PMNs exhibit defective spreading on Ab-coated targets, impaired formation of immunologic synapses, and absent tumor cytolysis. (Blood, 2001;97: 2478-2486) (C) 2001 by The American Society of Hematology.
引用
收藏
页码:2478 / 2486
页数:9
相关论文
共 73 条
[11]  
CAPRON M, 1987, J IMMUNOL, V139, P2059
[12]   INTEGRINS AND SIGNAL-TRANSDUCTION PATHWAYS - THE ROAD TAKEN [J].
CLARK, EA ;
BRUGGE, JS .
SCIENCE, 1995, 268 (5208) :233-239
[13]   Fc receptors are required in passive and active immunity to melanoma [J].
Clynes, R ;
Takechi, Y ;
Moroi, Y ;
Houghton, A ;
Ravetch, JV .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :652-656
[14]   Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J].
Clynes, RA ;
Towers, TL ;
Presta, LG ;
Ravetch, JV .
NATURE MEDICINE, 2000, 6 (04) :443-446
[15]  
CONNOR RI, 1990, J IMMUNOL, V145, P1483
[16]   A novel role for the beta 2 integrin CD11b/CD18 in neutrophil apoptosis: A homeostatic mechanism in inflammation [J].
Coxon, A ;
Rieu, P ;
Barkalow, FJ ;
Askari, S ;
Sharpe, AH ;
vonAndrian, UH ;
Arnaout, MA ;
Mayadas, TN .
IMMUNITY, 1996, 5 (06) :653-666
[17]   Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma:: Results of a phase II trial of rituximab [J].
Davis, TA ;
White, CA ;
Grillo-López, AJ ;
Velásquez, WS ;
Link, B ;
Maloney, DG ;
Dillman, RO ;
Williams, ME ;
Mohrbacher, A ;
Weaver, R ;
Dowden, S ;
Levy, R .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) :1851-1857
[18]   AGGREGATION OF COMPLEMENT RECEPTORS ON HUMAN-NEUTROPHILS IN THE ABSENCE OF LIGAND [J].
DETMERS, PA ;
WRIGHT, SD ;
OLSEN, E ;
KIMBALL, B ;
COHN, ZA .
JOURNAL OF CELL BIOLOGY, 1987, 105 (03) :1137-1145
[19]   ANTIBODIES AS CYTOTOXIC THERAPY [J].
DILLMAN, RO .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (07) :1497-1515
[20]   The immunological synapse and the actin cytoskeleton: molecular hardware for T cell signaling [J].
Dustin, ML ;
Cooper, JA .
NATURE IMMUNOLOGY, 2000, 1 (01) :23-29